Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29022402 | 1.00 | PPARG (0.53) | PPARGPPARAMDM4TP53MDM2 | |
| SCHEMBL31437101 | 1.00 | PPARG (0.53) | PPARGPPARAMDM4TP53MDM2 | |
| SCHEMBL30477935 | 1.00 | PPARG (0.53) | PPARGPPARAMDM4TP53MDM2 | |
| SCHEMBL19262281 | 0.92 | ITGB3 (0.55) | PPARGPPARAMDM2ITGB3ITGA2B | |
| SCHEMBL13261088 | 0.92 | ITGB3 (0.55) | PPARGPPARAMDM2ITGB3ITGA2B | |
| SCHEMBL30464881 | 0.92 | ITGB3 (0.55) | PPARGPPARAMDM2ITGB3ITGA2B | |
| SCHEMBL29772687 | 0.90 | ITGB3 (0.51) | MDM4TP53MDM2ITGB3ITGA2B | |
| SCHEMBL31097650 | 0.90 | MDM4 (0.51) | MDM4TP53MDM2ITGB3ITGA2B | |
| SCHEMBL2305323 | 0.90 | ITGB3 (0.57) | PPARGITGB3ITGA2BPTPN1 | |
| SCHEMBL2305316 | 0.90 | ITGB3 (0.57) | PPARGITGB3ITGA2BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| CN-112920086-B | Preparation method of L-tyrosine derivative | 长兴宜生药物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | disclosed |
| CN-112920086-A | Preparation method of L-tyrosine derivative | 长兴中昊化工有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | UNIV EMORY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| US-9700881-B2 | Heterocyclic coupling catalysts and methods related thereto | EMORY UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2017070157-A1 | REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015054337-A1 | HETEROCYCLIC COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2399599-A2 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | HAT1, CBR3, CBR1 | PPARG 382/4885PPARA 490/4885MDM4 910/4885 |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | PPARG 509/4885PPARA 545/4885MDM4 1009/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | PPARG 544/4885PPARA 787/4885MDM4 3040/4885 |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SELENOI | PPARG 1819/4885PPARA 1757/4885MDM4 3427/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | PPARG 325/4885PPARA 338/4885MDM4 1149/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | PPARG 354/4885PPARA 362/4885MDM4 1128/4885 |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SQOR | PPARG 1930/4885PPARA 1881/4885MDM4 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.